Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Clichy – page 258

3 418 clinical trials in Clichy, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Clichy at a glance
3 418
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 418 trials in Clichy

Open in trial search

Endometrial cancer+1

Not recruiting

Study of Retifanlimab Alone and in Combination with Drug Therapy for Adults with Advanced or Metastatic Endometrial Cancer Who Have Not Responded to Platinum Chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pemigatinib
  • Sponsor:Incyte Corp.

Non-small cell lung cancer

Not recruiting

Study of Tuvusertib and Cemiplimab for Patients with Non-Squamous Non-Small Cell Lung Cancer After Previous Treatments

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Merck Healthcare KGaA

Hormone receptor positive breast cancer+1

Not recruiting

Study of Giredestrant, Triptorelin, and Anastrozole in Premenopausal Women with ER-Positive/HER2-Negative Early Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Anastrozole
  • Sponsor:ETOP IBCSG Partners Foundation

Marginal zone lymphoma

Not recruiting

Study on [68Ga]Ga-PentixaFor and [18F]FDG PET/CT Imaging for Staging Marginal Zone Lymphoma in Patients with Confirmed Diagnosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pentixafor
  • Sponsor:Pentixapharm AG

Dementia Alzheimer's type

Not recruiting

Study on the Long-term Safety and Effects of AL002 and Florquinitau F18 in Patients with Alzheimer's Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Alector LLC

Neoplasm malignant+2

Not recruiting

Study on Larotrectinib for Treating Children with Advanced Solid Tumors with NTRK Fusion

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Larotrectinib Sulfate
  • Sponsor:Bayer AG

Squamous cell carcinoma of head and neck

Not recruiting

Study of ALE.C04 and Pembrolizumab for Adults with Recurrent or Metastatic Head and Neck Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ale.c04
  • Sponsor:Alentis Therapeutics AG

Chronic lymphocytic leukaemia

Not recruiting

Study Comparing Obinutuzumab and Venetoclax with Obinutuzumab and Chlorambucil for Untreated Chronic Lymphocytic Leukemia Patients with Other Health Conditions

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Chlorambucil
  • Sponsor:F. Hoffmann-La Roche AG

Non-small cell lung cancer

Not recruiting

Study on the Safety and Effectiveness of Telisotuzumab Vedotin for Patients with Previously Treated c-Met Positive Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Telisotuzumab Vedotin
  • Sponsor:Abbvie Deutschland GmbH & Co. KG

HIV infection

Not recruiting

Study on the Effects of GSK4004280 and GSK4011499 in Adults with HIV Infections

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Viiv Healthcare UK Limited

Hormone-refractory prostate cancer

Not recruiting

Study on Lutetium (177Lu) Vipivotide Tetraxetan and Androgen Receptor Inhibitors for Patients with Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Novartis Pharma AG

Malignant melanoma

Not recruiting

Study on the Safety and Effectiveness of Pembrolizumab, Vibostolimab, and Lenvatinib for Patients with PD-1 Refractory Melanoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Clichy

What the registry says about research in the country

01 Gastrointestinal Disorders

Innovative trials focusing on inflammatory bowel diseases and advanced treatment methods, including studies on Crohn's disease and ulcerative colitis using fecal microbiota transplantation as therapeutic approaches.

  • Crohn's Disease Management
  • Ulcerative Colitis Treatment
  • Short Bowel Syndrome

Research aims to improve patient outcomes through novel therapeutic interventions and treatment strategies.

02 Hepatobiliary Research

Comprehensive studies on liver diseases and biliary tract conditions, investigating new treatments for cirrhosis, portal hypertension, and various forms of liver cancer.

  • Hepatocellular Carcinoma
  • Biliary Tract Cancer
  • Liver Cirrhosis

Advanced therapeutic approaches combining immunotherapy and targeted treatments.

03 Pancreatic and Metabolic Disorders

Groundbreaking research on pancreatic cancer and metabolic conditions, evaluating novel drug combinations and treatment protocols.

  • Pancreatic Adenocarcinoma
  • Neuroendocrine Tumors
  • Metabolic Liver Disease

Focus on improving survival rates and treatment efficacy in advanced-stage diseases.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease? Our clinical trial advisor will do it for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.